CTRI/2019/06/019801招募中4 期
An Open-Label, Multicenter, Observational Study to Evaluate the Effectiveness and Safety of Nefopam Tablets in Acute Traumatic Pain.
试验速览
- 阶段
- 4 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. Male or female patients aged >=18 years
- •2. Inpatients or outpatients presenting with acute traumatic pain of moderate intensity defined as VAS score >=6 cm
- •3. Patients who have been prescribed nefopam hydrochloride tablets as per local label
- •4. Patients willing to comply with study procedure and able to provide written informed consent
排除标准
- •1. Patients taking any other analgesics within the period of up to 7 days prior to baseline
- •2. Pregnant and lactating women
- •3. Patients with cognitive impairment, alcohol abuse, or psychiatric illness that would affect the ability of the patient to complete patient diary and other assessments
- •4. Any other illness or conditions that does not justify patientâ??s participation in the study as judged by the investigator
研究者
相似试验
进行中（未招募）
不适用
An Open Label Observational Study of Safety and Efficacy of a Pharmaceutical grade Cannabis Medicine (MediCabilis™-CBD extract Oil) in Patients undergoing Medicinal Cannabis Therapy for Different IndicationsPost-traumatic stress disorderAnxietyMultiple sclerosisDementiaInsomniaACTRN12620000741987Bod Australia479
已完成
4 期
A observational study to evaluate the efficacy and safety of Ranibizumab in patients with visual impairment due to Diabetic Macular Edema(DMECTRI/2015/06/005945ovartis Healthcare Pvt Ltd
进行中（未招募）
1 期
Open-label study to evaluate the safety, local tolerability, systemic exposure, and efficacy of 1% GPB cream in adolescents with severe primary axillary hyperhidrosisSevere primary axillary hyperhidrosisMedDRA version: 20.0Level: PTClassification code 10020642Term: HyperhidrosisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2022-000922-46-PLDr. August Wolff GmbH & Co. KG Arzneimittel60
进行中（未招募）
1 期
Open-label study to evaluate the safety, local tolerability, systemic exposure, and efficacy of 1% GPB cream in adolescents with severe primary axillary hyperhidrosisEUCTR2022-000922-46-DEDr. August Wolff GmbH & Co. KG Arzneimittel40
已完成
4 期
An observational study to assess the profile of ranibizumab in patients with retinal vein occlusion in a real-world setting.CTRI/2015/07/005985ovartis Healthcare Pvt Ltd100